scispace - formally typeset
T

Thanh Tung Pham

Researcher at Yeungnam University

Publications -  7
Citations -  195

Thanh Tung Pham is an academic researcher from Yeungnam University. The author has contributed to research in topics: Cancer & Antigen. The author has an hindex of 4, co-authored 5 publications receiving 101 citations.

Papers
More filters
Journal ArticleDOI

Tumor-targeting, pH-sensitive nanoparticles for docetaxel delivery to drug-resistant cancer cells.

TL;DR: In vivo anticancer effect of DTX-LPH nanoparticles was further confirmed by the elevated levels of caspase-3 and poly ADP ribose polymerase found in the tumors after treatment.
Journal ArticleDOI

Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses.

TL;DR: This study provides a unique strategy for functionalizing exosome membrane with anti-CTLA-4 antibody via lipid-anchoring method to synergize efficacy of cancer vaccination and immune checkpoint blockade against the tumor.
Journal ArticleDOI

Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death

TL;DR: The results suggest that simultaneous PD-L1 inhibition via microRNAs and the induction of an immunogenic tumor microenvironment via low-dose cytotoxic drugs may improve cancer therapy efficacy.
Journal ArticleDOI

Targeting and clearance of senescent foamy macrophages and senescent endothelial cells by antibody-functionalized mesoporous silica nanoparticles for alleviating aorta atherosclerosis.

TL;DR: In this article, a CD9 antibody-modified mesoporous silica nanoparticles with a hyaluronidase-responsive drug release profile was developed for mitigating atherosclerosis through senescent cell clearance.
Journal ArticleDOI

Engineering New Immunotherapies against Cancer using Bacterial Outer Membrane Vesicles and Supported by Preclinical Data

TL;DR: Current research using purified rOMVs as immunotherapeutic vaccines is summarized and potential obstacles that still need to be adequately addressed are discussed to ensure success in human trials.